Formation of (R)-8-hydroxywarfarin in human liver microsomes: A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19

Drug Metabolism and Disposition

Volumn 24, Issue 5, 1996, Pages 610-614

  Wienkers, Larry C ^a   Wurden, Colleen J ^a   Storch, Elizabeth ^a   Kunze, Kent L ^a   Rettie, Allan E ^a   Trager, William F ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYWARFARIN; CYTOCHROME P450; DRUG METABOLITE; FLUCONAZOLE; FURAFYLLINE; MEPHENYTOIN; NORMEPHENYTOIN; OXYGENASE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INDUCTION; ENZYME MECHANISM; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL MARKERS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FLUCONAZOLE; HUMANS; HYDROXYLATION; KINETICS; MEPHENYTOIN; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MONOAMINE OXIDASE INHIBITORS; THEOPHYLLINE; TRANYLCYPROMINE; WARFARIN;

EID: 0029867317     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. A. E. Rettie, K. R. Korzekwa, K. L. Kunze, R. L. Lawrence, A. C. Eddy, T. Aoyama, H. V. Gelboin, F. J. Gonzalez, and W. F. Trager: Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: a role for P450 2C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5, 54-59 (1992).
2. W. R. Brian, M.-A. Sari, M. Iwasaki, T. Shimada, L. Kaminsky, and F. P. Guengerich: Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 29, 11280-11291 (1990).
3. R. L. Lawrence, A. E. Rettie, A. C, Eddy, and W. F. Trager: Chemical synthesis, absolute configuration and stereochemistry of 10-hydroxywarfarin: a major oxidative metabolite of (R)-warfarin from hepatic microsomal preparations. Chirality 2, 96-105 (1990).
4. A. E. Rettie, A. C. Eddy, L. D. Heimark, M. Gibaldi, and W. F. Trager: Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab. Dispos. 17, 265-270 (1989).
5. S. A. Wrighton, J. C. Stevens, G. W. Becker, and M. VandenBranden: Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306, 240-245 (1993).
6. J. A. Goldstein, M. B. Faletto, M. Romkes-Sparks, T. Sullivan, J. L. Raucy, S. Kitareewan, J. M. Lasker, and B. I. Ghanayem: Evidence that P450 2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33, 1743-1752 (1994).
7. L. S. Kaminsky, S. M. F. de Morais, M. B. Faletto, D. A. Dunbar, and J. A. Goldstein: Correlation of human cytochrome P4502C substrate specificity with primary structure: warfarin as a probe. Mol. Pharmacol. 43, 234-239 (1993).
8. K. L. Kunze, L. C. Wienkers, K. E. Thummel, and W. F. Trager: Warfarin-fluconazole. I. Inhibition of the human cytochrome P450 dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab. Dispos. 24, 414-421 (1996).
9. D. J. Black, K. L. Kunze, L. C. Winkers, B. E. Gidal, T. L. Seaton, N. D. McDonnell, J. S. Evans, I. E. Bauwens, and W. F. Trager: Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab. Dispos. 24, 422-428 (1996).
10. Z. Zhang, M. J. Fasco, Z. Huang, F. P. Guengerich, and L. S. Kaminsky: Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. Drug Metab. Dispos. 23, 1339-1345 (1995).
11. R. W. Estabrook, J. Peterson, J. Baron, and A. Hildebrant: The spectrophotometric measurement of turbid suspensions of cytochromes associated with drug metabolism. Methods Pharmacol. 2, 303-350 (1972).
12. L. D. Heimark, S. Toon, D. C. Swinney, and W. F. Trager: The synthesis of deuterium labelled metabolites of warfarin and phenprocoumon. J. Labelled Compds. Radiopharm. 23, 137-148 (1985).
13. J. J. Spurlock and H. R. Henze: The synthesis of colored derivatives of nirvanol. J. Am. Chem. Soc. 60, 3005-3007 (1938).
14. H. Sabotka, M. F. Holzman, and J. Kahn: Optically active 5,5′-disubstituted hydantoins. J Am. Chem. Soc. 54, 4697-4702 (1932).
15. V. G. Grimmer, J. Jacob, and H. Schafer: Die gaschromatographische bestimmung von 5,5-diphenylhydantoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin im blut. Arzneim-Forsch. 19, 1287-1290 (1969).
16. K. L. Kunze and W. F. Trager: Isoform-selective mechanism based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6, 649-656 (1993).
17. E. D. Bush, L. K. Low, and W. F. Trager: A sensitive and specific stable isotope assay for warfarin and its metabolites. Biomed. Mass Spectrom. 10, 395-398 (1983).
18. T. Inaba, M. Jurima, W. A. Mahon, and W. Kalow: In vitro studies of two isozymes of human liver cytochrome P450. Drug Metab. Dispos. 13, 443-448 (1985).